Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Raw Materials (2016 - 2022)

Usana Health Sciences has reported Raw Materials over the past 12 years, most recently at $24.6 million for Q3 2022.

  • Quarterly Raw Materials fell 9.4% to $24.6 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $24.6 million through Jul 2022, down 9.4% year-over-year, with the annual reading at $30.3 million for FY2022, 6.89% up from the prior year.
  • Raw Materials was $24.6 million for Q3 2022 at Usana Health Sciences, down from $30.6 million in the prior quarter.
  • Over five years, Raw Materials peaked at $30.9 million in Q4 2021 and troughed at $14.1 million in Q1 2020.
  • The 5-year median for Raw Materials is $22.5 million (2019), against an average of $23.6 million.
  • Year-over-year, Raw Materials tumbled 37.08% in 2020 and then surged 93.29% in 2021.
  • A 5-year view of Raw Materials shows it stood at $19.5 million in 2018, then fell by 18.58% to $15.9 million in 2019, then surged by 42.13% to $22.6 million in 2020, then soared by 37.05% to $30.9 million in 2021, then fell by 20.37% to $24.6 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Raw Materials are $24.6 million (Q3 2022), $30.6 million (Q2 2022), and $30.3 million (Q1 2022).